iifl-logo

Natco Pharma Ltd Balance Sheet

889.25
(-1.51%)
Apr 25, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

35.8

36.5

36.5

36.5

Preference Capital

0

0

0

0

Reserves

5,556.5

4,665.5

4,155.4

4,054.6

Net Worth

5,592.3

4,702

4,191.9

4,091.1

Minority Interest

Debt

366.1

161.1

399.5

256.4

Deferred Tax Liability Net

208.7

205.4

157.6

106.2

Total Liabilities

6,167.1

5,068.5

4,749

4,453.7

Fixed Assets

2,420.6

2,296.6

2,302.9

2,229.3

Intangible Assets

Investments

741.7

657.5

550

337

Deferred Tax Asset Net

215.8

176.5

127.6

64.9

Networking Capital

1,924.1

1,525.9

1,667.6

1,559.7

Inventories

596.9

616

697.7

769.2

Inventory Days

169.79

Sundry Debtors

1,076.6

793.1

575.6

399.8

Debtor Days

88.25

Other Current Assets

846.2

612.7

750.9

754.4

Sundry Creditors

-216.1

-214.4

-172.3

-174.5

Creditor Days

38.51

Other Current Liabilities

-379.5

-281.5

-184.3

-189.2

Cash

864.9

412

100.9

262.8

Total Assets

6,167.1

5,068.5

4,749

4,453.7

Natco Pharma : related Articles

Natco Pharma Gets USFDA Approval for Bosentan 32mg Tablets
12 Feb 2025|11:14 AM

The drug enhances the flow of blood through the lungs, allowing children with PAH to breathe and improve their ability to engage in physical activity.

Read More
Natco Pharma Sells Telangana Land for ₹115.57 Crore
1 Dec 2024|07:16 PM

The company was ensured that the sale of the land and building did not constitute part of its operational assets so that the sale will, in no way, impact the company's business operations

Read More
Natco Pharma Q2 Profit Surges 83%, Declares Interim Dividend
12 Nov 2024|10:26 PM

The revenue for the September quarter rose by 33% to ₹1,371 crore from ₹1,031 crore in the corresponding period last year.

Read More
Natco Pharma settles US patent case over generic Ozempic
7 Oct 2024|01:52 PM

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

Read More
Cancer Patients Benefit as GST on Medications Slashed
10 Sep 2024|12:22 PM

The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.

Read More
Natco Pharma invests $8 million in US biotech firm eGenesis
4 Sep 2024|03:28 PM

Natco Pharma disclosed that its subsidiary will invest USD 8 million in eGenesis, acquiring a total of 40,629,761 shares.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.